Cargando…
TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
BACKGROUND: TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to e...
Autores principales: | Kim, Ji‐Yeon, Jung, Jaeyun, Kim, Kyoung‐Mee, Lee, Jeeyun, Im, Young‐Hyuck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278489/ https://www.ncbi.nlm.nih.gov/pubmed/37081749 http://dx.doi.org/10.1002/cam4.5953 |
Ejemplares similares
-
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017) -
Clinical sequencing to assess tumor mutational burden as a useful
biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021) -
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients
por: Cho, Sung-Yup, et al.
Publicado: (2017) -
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016) -
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
por: Wang, Shuhang, et al.
Publicado: (2020)